DK3823623T3 - Substitueret amino-pyrimidinforbindelse til anvendelse i en fremgangsmåde til behandling og forebyggelse af multipel sklerose - Google Patents

Substitueret amino-pyrimidinforbindelse til anvendelse i en fremgangsmåde til behandling og forebyggelse af multipel sklerose Download PDF

Info

Publication number
DK3823623T3
DK3823623T3 DK19768898.9T DK19768898T DK3823623T3 DK 3823623 T3 DK3823623 T3 DK 3823623T3 DK 19768898 T DK19768898 T DK 19768898T DK 3823623 T3 DK3823623 T3 DK 3823623T3
Authority
DK
Denmark
Prior art keywords
pyrimide
treating
compound
multiple sclerosis
substituted amino
Prior art date
Application number
DK19768898.9T
Other languages
English (en)
Inventor
Martin Dyroff
David Mitchell
Orestis Papasouliotis
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of DK3823623T3 publication Critical patent/DK3823623T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK19768898.9T 2018-07-20 2019-07-19 Substitueret amino-pyrimidinforbindelse til anvendelse i en fremgangsmåde til behandling og forebyggelse af multipel sklerose DK3823623T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862700977P 2018-07-20 2018-07-20
US201862730184P 2018-09-12 2018-09-12
US201962839273P 2019-04-26 2019-04-26
PCT/IB2019/056198 WO2020016850A1 (en) 2018-07-20 2019-07-19 A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis

Publications (1)

Publication Number Publication Date
DK3823623T3 true DK3823623T3 (da) 2025-01-02

Family

ID=67953828

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19768898.9T DK3823623T3 (da) 2018-07-20 2019-07-19 Substitueret amino-pyrimidinforbindelse til anvendelse i en fremgangsmåde til behandling og forebyggelse af multipel sklerose

Country Status (22)

Country Link
US (1) US12251382B2 (da)
EP (1) EP3823623B1 (da)
JP (1) JP7724151B2 (da)
KR (1) KR102912872B1 (da)
CN (1) CN112437665A (da)
AU (2) AU2019306828A1 (da)
BR (1) BR112021000893A2 (da)
CA (1) CA3106772A1 (da)
DK (1) DK3823623T3 (da)
ES (1) ES3009670T3 (da)
FI (1) FI3823623T3 (da)
HR (1) HRP20241737T1 (da)
HU (1) HUE069840T2 (da)
IL (1) IL280197B2 (da)
MX (1) MX2021000094A (da)
PL (1) PL3823623T3 (da)
PT (1) PT3823623T (da)
SG (1) SG11202100518TA (da)
TW (1) TWI879737B (da)
UA (1) UA127744C2 (da)
WO (1) WO2020016850A1 (da)
ZA (1) ZA202101118B (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3168146A1 (en) * 2020-01-20 2021-07-29 Genzyme Corporation Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms)
TWI899163B (zh) * 2020-02-28 2025-10-01 美商建南德克公司 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法
BR112023021235A2 (pt) 2021-05-14 2023-12-12 Loxo Oncology Inc Formas cocristalinas de um inibidor da tirosina quinase de bruton
US20240327379A1 (en) * 2021-07-15 2024-10-03 Sandoz Ag Mandelate form of 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one
US20260000669A1 (en) 2022-06-24 2026-01-01 Merck Patent Gmbh Treatment regimen for autoimmune diseases and inflammatory diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10060388A1 (de) * 2000-12-05 2002-06-06 Merck Patent Gmbh Verwendung von Pyrazolo [4,3-d]pyrimidinen
WO2011156900A2 (en) * 2010-06-17 2011-12-22 Waratah Pharmaceuticals Inc. Compounds, compositions and methods for treatment of multiple sclerosis
US9073947B2 (en) * 2011-06-10 2015-07-07 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
TW201728592A (zh) * 2012-01-10 2017-08-16 林伯士艾瑞斯公司 Irak抑制劑及其用途
TW201804997A (zh) * 2012-05-02 2018-02-16 以色列商泰瓦藥品工業有限公司 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途
KR102780243B1 (ko) 2015-11-17 2025-03-14 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물을 사용하여 다발성 경화증을 치료하는 방법
US10464923B2 (en) * 2017-02-27 2019-11-05 Merck Patent Gmbh Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone

Also Published As

Publication number Publication date
TW202019425A (zh) 2020-06-01
HUE069840T2 (hu) 2025-04-28
AU2025203171A1 (en) 2025-05-22
UA127744C2 (uk) 2023-12-20
MX2021000094A (es) 2021-03-25
JP7724151B2 (ja) 2025-08-15
EP3823623B1 (en) 2024-10-09
BR112021000893A2 (pt) 2021-04-13
PL3823623T3 (pl) 2025-03-24
ZA202101118B (en) 2025-06-25
TWI879737B (zh) 2025-04-11
US20210260060A1 (en) 2021-08-26
EP3823623A1 (en) 2021-05-26
KR102912872B1 (ko) 2026-01-15
IL280197A (en) 2021-03-01
IL280197B1 (en) 2026-03-01
CN112437665A (zh) 2021-03-02
JP2021532104A (ja) 2021-11-25
KR20210034623A (ko) 2021-03-30
FI3823623T3 (fi) 2025-01-09
WO2020016850A1 (en) 2020-01-23
IL280197B2 (en) 2026-07-01
US12251382B2 (en) 2025-03-18
ES3009670T3 (en) 2025-03-31
PT3823623T (pt) 2025-01-06
AU2019306828A1 (en) 2021-03-11
HRP20241737T1 (hr) 2025-02-28
SG11202100518TA (en) 2021-02-25
CA3106772A1 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
DK3755356T3 (da) Sammensætninger, anordninger, systemer, sæt og fremgangsmåder til behandling af en hudtilstand
EP3860529A4 (en) Apparatus and methods for scaffolding
EP3855818C0 (en) METHOD AND DEVICE FOR POSITIONING
DK3630761T3 (da) Kras-g12c-inhibitorer og fremgangsmåder til anvendelse af disse
DK3878842T3 (da) (hetero)arylimidazolforbindelser og midler til bekæmpelse af skadelige organismer
DK3775909T3 (da) Midler og fremgangsmåder til glykoprofilering af et protein
DK3880660T3 (da) Forbindelser og sammensætninger til behandling af tilstande forbundet med nlrp-aktivitet
PL4460004T3 (pl) Urządzenie i sposób kodowania wideo w oparciu o filtrowanie
DK3386518T3 (da) Metoder og sammensætninger til behandling af en serpinc1-associeret forstyrrelse
DK4434585T3 (da) Forbindelser og fremgangsmåder til reduktion af snca-ekspression
EP3849254A4 (en) POSITIONING PROCESS AND APPARATUS
DK4169491T3 (da) Indretninger og fremgangsmåde til behandling af bruxisme
DK3793588T3 (da) Fremgangsmåder til behandling af hæmofili a
DK3447056T3 (da) Multikinasehæmmerforbindelse, krystalform og anvendelse deraf
DK3736382T3 (da) Erosionsbeskyttelsesenhed og erosionsbeskyttelsesfremgangsmåde
EP3883318A4 (en) SIDE LINK COMMUNICATION METHOD AND APPARATUS
IL288744A (en) Novel additive nanomanufacturing system and method
IL286040A (en) Methods of treating al amyloidosis
EP3864593C0 (en) PROJECT MANAGEMENT SYSTEMS AND PROCESSES INCORPORATING A PROXIMITY-BASED ASSOCIATION
DK3569762T3 (da) Fremgangsmåde og anordning til udbredning af vasketøjsstykker
DK3952858T3 (da) Fremgangsmåde til behandling af tumorer
DK3698015T3 (da) Et system og en fremgangsmåde til rengøring af et ringformet område i et borehul
IL270721A (en) Systems and methods for correlated error event mitigation for variant calling
DK3994420T3 (da) System og fremgangsmåde til beskyttelse af en genstand
IL286330A (en) Casing for apparatus, apparatus and method